Abstract
The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux-inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine-based combinations; the molecular derangements that promote neoplastic transformation; the role of COX-2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.
Keywords:
Barrett's adenocarcinoma; COXIBs, PPIs; OESO; animal reflux-inflammation models; biomarkers; elofrnithine; statins.
© 2014 New York Academy of Sciences.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Barrett Esophagus / diagnosis
-
Barrett Esophagus / metabolism
-
Barrett Esophagus / prevention & control
-
Biomarkers, Tumor / metabolism
-
Cell Transformation, Neoplastic / metabolism
-
Cyclooxygenase 2 Inhibitors / therapeutic use
-
Eflornithine / therapeutic use
-
Esophageal Neoplasms / diagnosis*
-
Esophageal Neoplasms / metabolism
-
Esophageal Neoplasms / prevention & control*
-
Gastroesophageal Reflux / diagnosis
-
Gastroesophageal Reflux / metabolism
-
Gastroesophageal Reflux / prevention & control
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Paris
-
Proton Pump Inhibitors / therapeutic use
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Cyclooxygenase 2 Inhibitors
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Proton Pump Inhibitors
-
Eflornithine